{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:47:36Z","timestamp":1787212056195,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rmr.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:10:06Z","timestamp":1713784206000},"page":"372-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effets ind\u00e9sirables des bioth\u00e9rapies de l\u2019asthme s\u00e9v\u00e8re"],"prefix":"10.1016","volume":"41","author":[{"given":"G.","family":"Dargentolle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Beltramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Poisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2024.04.001_bib0405","unstructured":"\u00ab\u00a0santepubliquefrance.fr\u00a0\u00bb."},{"key":"10.1016\/j.rmr.2024.04.001_bib0410","first-page":"100898","article-title":"Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A)","volume":"81","author":"Raherison-Semjen","year":"2022","journal-title":"Respir Med Res"},{"key":"10.1016\/j.rmr.2024.04.001_bib0415","unstructured":"\u00ab\u00a0Global Initiative for Asthma. 2021\u00a0GINA Main Report, global strategy for asthma management and prevention (2021\u00a0update)\u00a0\u00bb."},{"key":"10.1016\/j.rmr.2024.04.001_bib0530","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1385\/CRIAI:29:1:031","article-title":"Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody","volume":"29","author":"Deniz","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0425","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1081-1206(10)62175-8","article-title":"Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma","volume":"91","author":"Berger","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0515","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0520","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.rmr.2024.04.001_bib0560","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5\u00a0years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.04.001_bib0550","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5\u00a0receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.04.001_bib0540","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0565","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.chest.2022.01.071","article-title":"Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: an analysis of the phase 3, open-label extension TRAVERSE trial","volume":"162","author":"Sher","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2024.04.001_bib0570","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/02770903.2022.2082309","article-title":"One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study","volume":"60","author":"Shinkai","year":"2023","journal-title":"J Asthma"},{"key":"10.1016\/j.rmr.2024.04.001_bib0545","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0510","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.04.001_bib0555","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3\u00a0extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0535","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3\u00a0trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.04.001_bib0525","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0420","doi-asserted-by":"crossref","first-page":"2000117","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5\u00a0monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.04.001_bib0435","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.alit.2022.03.005","article-title":"Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology?","volume":"71","author":"Nishiyama","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.04.001_bib0440","doi-asserted-by":"crossref","first-page":"e00599","DOI":"10.1002\/rcr2.599","article-title":"Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5\u00a0receptor antibody","volume":"8","author":"Takimoto","year":"2020","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.rmr.2024.04.001_bib0445","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.alit.2022.02.007","article-title":"A case of organizing pneumonia in an asthmatic patient treated with benralizumab","volume":"71","author":"Kitajima","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.04.001_bib0450","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2024.04.001_bib0455","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0460","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.04.001_bib0465","first-page":"e27670","article-title":"Dupilumab-associated eosinophilic granulomatosis with polyangiitis","volume":"14","author":"Persaud","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.rmr.2024.04.001_bib0430","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/TCRM.S207402","article-title":"A case of chronic eosinophilic pneumonia in a patient treated with dupilumab","volume":"15","author":"Menzella","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.rmr.2024.04.001_bib0470","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/all.14964","article-title":"Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia","volume":"76","author":"Lommatzsch","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.04.001_bib0475","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13\u00a0pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0480","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0485","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","article-title":"Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion","volume":"10","author":"Buhl","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.04.001_bib0490","first-page":"100821","article-title":"Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma","volume":"79","author":"Descamps","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.rmr.2024.04.001_bib0495","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.rmr.2022.06.004","article-title":"Diagnostic d\u2019une granulomatose \u00e9osinophilique avec polyang\u00e9ite sous benralizumab","volume":"39","author":"Carrette","year":"2022","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.04.001_bib0500","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","article-title":"Churg-Strauss syndrome associated with omalizumab","volume":"19","author":"Pu\u00e9chal","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0505","first-page":"214","article-title":"Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review","volume":"38","author":"Basta","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0575","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12883-022-02849-1","article-title":"Mepolizumab-induced posterior reversible encephalopathy syndrome (PRES), a new patient report","volume":"22","author":"Puram","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0580","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review","volume":"59","author":"Israel","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.rmr.2024.04.001_bib0585","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.20138","article-title":"Dupilumab-associated arthralgia: an observational retrospective study in VigiBase\u00ae","volume":"185","author":"Chr\u00e9tien","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0590","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0595","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23\u00a0expression by IL-4\u00a0and IL-13\u00a0as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rmr.2024.04.001_bib0600","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1016\/j.jaip.2021.05.027","article-title":"Rheumatoid arthritis-like polyarthralgia after the initiation of omalizumab treatment: a case series","volume":"9","author":"To","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.04.001_bib0605","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/annrheumdis-2020-218902","article-title":"Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis","volume":"80","author":"Andreev","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rmr.2024.04.001_bib0610","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.rmr.2024.04.001_bib0615","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.04.001_bib0620","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0625","first-page":"488","article-title":"Management of dupilumab-associated conjunctivitis in atopic dermatitis","volume":"17","author":"Aszodi","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.rmr.2024.04.001_bib0630","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/ICO.0000000000002854","article-title":"Corneal perforation in patients under treatment with dupilumab for atopic dermatitis","volume":"41","author":"Phylactou","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.rmr.2024.04.001_bib796","doi-asserted-by":"crossref","unstructured":"Y. Nahum, M. Mimouni, E. Livny, I. Bahar, E. Hodak, et Y. A. Leshem, \u00ab Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment \u00bb, Br. J. Ophthalmol., vol. 104, no 6, p. 776\u2011779, juin 2020","DOI":"10.1136\/bjophthalmol-2019-315010"},{"key":"10.1016\/j.rmr.2024.04.001_bib0635","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.18932","article-title":"French atopic dermatitis network from the groupe de recherche sur l\u2019eczema atopique (GREAT), France. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0640","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab-associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0645","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2340\/00015555-3244","article-title":"Alopecia areata after omalizumab treatment for chronic spontaneous urticaria","volume":"99","author":"Magen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0650","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1600-0625.1995.tb00256.x","article-title":"Mast cells as modulators of hair follicle cycling","volume":"4","author":"Maurer","year":"1995","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0655","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1365-2133.2012.10817.x","article-title":"Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report","volume":"166","author":"Dammak","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0660","doi-asserted-by":"crossref","first-page":"e233161","DOI":"10.1136\/bcr-2019-233161","article-title":"Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma","volume":"13","author":"Nixon","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.rmr.2024.04.001_bib0665","doi-asserted-by":"crossref","first-page":"e0270906","DOI":"10.1371\/journal.pone.0270906","article-title":"Short communication: comments on hair disorders associated with dupilumab based on VigiBase","volume":"17","author":"Park","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2024.04.001_bib0670","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","article-title":"Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature","volume":"148","author":"Beaziz","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0675","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0680","doi-asserted-by":"crossref","first-page":"e15064","DOI":"10.1111\/dth.15064","article-title":"Alcohol flushing during dupilumab therapy: an emerging adverse event","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.rmr.2024.04.001_bib0685","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/crj.12998","article-title":"Disseminated herpes zoster following treatment with benralizumab","volume":"13","author":"Mishra","year":"2019","journal-title":"Clin Respir J"},{"key":"10.1016\/j.rmr.2024.04.001_bib0690","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1684\/ejd.2021.3995","article-title":"Development of lichen planus following benralizumab treatment","volume":"31","author":"Morimoto","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0695","doi-asserted-by":"crossref","first-page":"e05930","DOI":"10.1002\/ccr3.5930","article-title":"Case of benralizumab-induced exacerbations of chronic spontaneous urticaria","volume":"10","author":"Magen","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.rmr.2024.04.001_bib0700","doi-asserted-by":"crossref","first-page":"e12038","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.rmr.2024.04.001_bib0705","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0710","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fc\u03b3 receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rmr.2024.04.001_bib0715","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13223-020-00446-w","article-title":"Anaphylaxis to three humanized antibodies for severe asthma: a case study","volume":"16","author":"Jingo","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0720","first-page":"66","article-title":"Hypersensitivity reactions to multiple biologicals in a pediatric patient with severe persistent asthma","volume":"36","author":"Angirekula","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.rmr.2024.04.001_bib0725","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18176\/jiaci.0492","article-title":"Anaphylaxis to mepolizumab and omalizumab in a single patient: is polysorbate the culprit?","volume":"30","author":"Bergmann","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0730","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.intimp.2012.10.021","article-title":"Complement activation associated with polysorbate 80\u00a0in beagle dogs","volume":"15","author":"Qiu","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0735","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0740","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2024.04.001_bib0745","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.alit.2021.01.001","article-title":"Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance","volume":"70","author":"Nakamura","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.04.001_bib0750","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.anai.2015.04.014","article-title":"Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience","volume":"115","author":"Harrison","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0755","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1744666X.2020.1724089","article-title":"Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases","volume":"16","author":"Jackson","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0760","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.anpedi.2013.10.031","article-title":"Trombocitopenia por omalizumab [Thrombocytopenia due to omalizumab]","volume":"80","author":"Lopez-Rodriguez","year":"2014","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.rmr.2024.04.001_bib0765","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0770","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JAA.S363398","article-title":"Efficacy and safety of omalizumab treatment over a 16-year follow-up: when a clinical trial meets real-life","volume":"15","author":"Menzella","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.rmr.2024.04.001_bib0775","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/DER.0000000000000651","article-title":"Acute pancreatitis in 2\u00a0adolescent boys on dupilumab therapy for atopic dermatitis","volume":"32","author":"Stoner","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.rmr.2024.04.001_bib0780","first-page":"20-0030","article-title":"Painless thyroiditis in a dupilumab-treated patient","volume":"2020","author":"Narantsatsral","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.rmr.2024.04.001_bib0785","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s13340-021-00526-1","article-title":"Dupilumab-related type 1\u00a0diabetes in a patient with atopic dermatitis: a case report","volume":"13","author":"Kurokawa","year":"2021","journal-title":"Diabetol Int"},{"key":"10.1016\/j.rmr.2024.04.001_bib0790","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.04.001_bib0795","doi-asserted-by":"crossref","first-page":"220013","DOI":"10.1183\/20734735.0013-2022","article-title":"Challenges in the successful management of asthma during conception, pregnancy and delivery","volume":"18","author":"Gade","year":"2022","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.rmr.2024.04.001_bib0400","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/02770903.2021.1971700","article-title":"Factors leading to discontinuation of biologic therapy in patients with severe asthma","volume":"59","author":"Silver","year":"2022","journal-title":"J Asthma"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T19:54:42Z","timestamp":1715802882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842524001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0761842524001906"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2024.04.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables des bioth\u00e9rapies de l\u2019asthme s\u00e9v\u00e8re","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}